MucoShield AB – A new preventive treatment for chemotherapy induced oral mucositis, with a broader focus on oral health
Mucoshield AB is developing an innovative, locally administered treatment to prevent chemotherapy induced oral mucositis (CIOM), a serious and common condition among cancerpatients. The treatment principle is based on the assumption that temporary modulation of local blood flow in the oral mucosa can reduce tissue exposure to cytotoxic drugs. This protective effect will be evaluated in upcoming studies, with the goal of preventing the development of severe oral mucositis.